Puma Biotechnology (NASDAQ: PBYI) revenue
Puma Biotechnology reported revenue of $228.4m for fiscal 2025, 0.9% less than in fiscal 2024 ($230.5m). Since fiscal 2017 its revenue has grown by 724.9%, an average growth of 30.2% a year.
Puma Biotechnology's revenue has fallen for 2 years in a row, and its best year of the last 9 was fiscal 2019. The biggest drop was in fiscal 2020, −17.3%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $228.4m | −0.9% | $37.3m | 16.3% |
| 2024 | $230.5m | −2.2% | $31.0m | 13.4% |
| 2023 | $235.6m | +3.3% | $32.6m | 13.9% |
| 2022 | $228.0m | −9.9% | $23.7m | 10.4% |
| 2021 | $253.2m | +12.5% | $1.3m | 0.5% |
| 2020 | $225.1m | −17.3% | −$30.4m | −13.5% |
| 2019 | $272.3m | +8.5% | −$39.0m | −14.3% |
| 2018 | $251.0m | +806.6% | −$94.7m | −37.7% |
| 2017 | $27.7m | — | −$292.4m | −1,056.1% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Puma Biotechnology revenue compared with its sector
By revenue for its latest fiscal year, Puma Biotechnology ranks 242nd of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Puma Biotechnology, −0.9%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 240th | Anaptysbio | $234.6m | 157.0% |
| 241st | Cerus | $233.8m | 16.1% |
| 242nd | Puma Biotechnology | $228.4m | −0.9% |
| 243rd | Axogen | $225.2m | 20.2% |
| 244th | IDEAYA Biosciences | $218.7m | 3,024.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Puma Biotechnology
- How much revenue did Puma Biotechnology make in fiscal 2025?
- Puma Biotechnology reported revenue of $228.4m for fiscal 2025, compared with $230.5m in fiscal 2024.
- How much has the revenue of Puma Biotechnology grown?
- Between fiscal 2017 and fiscal 2025 it went from $27.7m to $228.4m: 724.9% more, an average growth of 30.2% a year.
- What was the best year for revenue at Puma Biotechnology?
- Of its last 9 fiscal years, fiscal 2019, with $272.3m.
- Where does Puma Biotechnology rank in its sector by revenue?
- It ranks 242nd of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Puma Biotechnology come from?
- From the annual report (Form 10-K) that Puma Biotechnology files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Puma Biotechnology files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017. More on Puma Biotechnology: the Puma Biotechnology page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.